双鹭药业(002038) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥193,122,918.04, a decrease of 29.20% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥403,954.63, down 99.44% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,550,721.39, a decrease of 83.81% compared to the previous year[5] - The weighted average return on net assets was 0.01%, down 1.35% year-on-year[5] - The company experienced a 6.09% year-on-year decline in revenue from January to September due to price reductions from national procurement tenders[7] - The net profit attributable to shareholders was $317,568,080.90, up from $237,948,276.96, reflecting a growth of 33.4%[25] - The net profit attributable to the parent company increased to $317.57 million, compared to $239.28 million in the previous period, representing a growth of approximately 32.7%[58] - Basic and diluted earnings per share improved to $0.3091 from $0.2316, an increase of about 33.5%[58] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,067,610,368.99, an increase of 3.26% from the end of the previous year[5] - The total assets increased to $6,067,610,368.99, compared to $5,875,839,869.74 in the previous period[41] - The total liabilities and equity amounted to $6,067,610,368.99, an increase from $5,875,839,869.74 in the previous period[41] - The company's total liabilities decreased slightly, with accounts payable reducing to $168.24 million from $176.18 million, a decrease of about 4.8%[61] - The company has maintained a strong liquidity position with total current assets amounting to $2.05 billion, compared to $1.99 billion previously, an increase of approximately 2.9%[61] Cash Flow - The cash flow from operating activities for the year-to-date was ¥224,281,650.22, a decrease of 17.70% compared to the same period last year[5] - The net cash flow from operating activities was $224,281,650.22, a decrease of 17.7% compared to $272,519,850.78 in the previous period[21] - The total cash outflow from investing activities was $230,924,812.33, down 10% from $256,565,690.10 in the prior period, resulting in a net cash flow of -$75,960,407.51[21] - The cash flow from financing activities remained unchanged at -$102,735,000.00, consistent with the previous period[21] - The net increase in cash and cash equivalents was $45,588,113.35, compared to $81,543,536.73 in the prior period, indicating a decline of 44%[21] - The cash flow from investment activities showed a decrease in cash inflow to $154,964,404.82 from $168,374,680.35[21] - The company reported a decrease in cash paid for operating activities, totaling $563,284,455.89, down from $661,928,579.43[21] - Cash inflow from operating activities decreased to $787.57 million from $934.45 million, a decline of approximately 15.7% year-over-year[43] - The company reported a significant increase in cash received from tax refunds, rising to $6.64 million from $5.09 million, an increase of 30.5%[43] - The company's cash and cash equivalents rose to $735.40 million, up from $595.04 million, marking a substantial increase of 23.6%[55] Government Support and Fair Value Changes - The company received government subsidies amounting to ¥2,424,577.63 during the reporting period[5] - The company reported a loss of ¥23,109,919.75 from fair value changes of trading financial assets during the year-to-date[5] - The fair value change of other non-current financial assets increased by 577.08% year-over-year, although the total amount decreased by approximately $2.39 million in the current period[52] Shareholder Information - The company reported a total of 80,352 common shareholders at the end of the reporting period[8] Strategic Focus - The company is focusing on expanding its market presence and developing new products, although specific details on new products and technologies were not disclosed in the report[47]